1 2	GWAS including 82,707 subjects identifies functional coding variant in <i>OPRM1</i> gene associated with opioid use disorder
3	
4 5 6 7 8 9	Hang Zhou, Ph.D., <sup>1,2</sup> Christopher T. Rentsch, Ph.D., <sup>2,3,4</sup> Zhongshan Cheng, Ph.D., <sup>1,2</sup> Rachel L. Kember, Ph.D., <sup>5,6</sup> Yaira Z. Nunez, B.S., <sup>1,2</sup> Janet P. Tate, M.P.H., Sc.D., <sup>2,3</sup> Cecilia Dao, Ph.D., <sup>2,3</sup> Ke Xu, M.D., <sup>1,2</sup> Renato Polimanti, Ph.D., <sup>1,2</sup> Lindsay A. Farrer, Ph.D., <sup>7,8</sup> Amy C. Justice, M.D., Ph.D., <sup>2,3,9</sup> Henry R. Kranzler, M.D., <sup>6,10</sup> the VA Million Veteran Program, Joel Gelernter, M.D., <sup>1,2,11*</sup>

- 10 11
- <sup>1</sup>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA 12
- 13 <sup>2</sup>Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA
- <sup>3</sup>Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA 14
- <sup>4</sup>Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical 15
- Medicine, London, UK 16
- 17 <sup>5</sup>Department of Genetics, University of Pennsylvania Perelman School of Medicine,
- 18 Philadelphia, PA, USA
- <sup>6</sup>Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA 19
- 20 <sup>7</sup>Departments of Medicine (Biomedical Genetics), Neurology, and Ophthalmology, Boston
- 21 University School of Medicine, Boston, MA, USA
- <sup>8</sup>Departments of Biostatistics, and Epidemiology, Boston University School of Public Health, 22
- 23 Boston, MA, USA
- <sup>9</sup>Yale School of Public Health, New Haven, CT, USA 24
- <sup>10</sup>Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, 25
- Philadelphia, PA, USA 26
- <sup>11</sup>Departments of Genetics and Neuroscience, Yale University School of Medicine, New Haven, 27
- 28 CT, USA

- \*Corresponding Author: Joel Gelernter, Department of Psychiatry, Yale School of Medicine, 30
- Veterans Affairs Connecticut Healthcare System, 116A2, 950 Campbell Ave, West Haven, CT 31
- 06516, USA. Phone: +1 (203) 494-6326 x3590; Fax: +1 (203) 937-4741; Email: 32
- joel.gelernter@yale.edu. 33

# 34 Abstract

One way to address the current crisis in opioid use is to improve our understanding of the 35 biological mechanisms of opioid use disorder (OUD). We completed a primary GWAS of 36 37 electronic health record-defined OUD in European-ancestry participants in the Million Veteran 38 Program (MVP) sample, which included 8,529 affected subjects and 71,200 opioid-exposed 39 controls. In the MVP alone, there were no genome-wide significant (GWS) associations. We then subjected the MVP and additional OUD GWAS results from the Yale-Penn and SAGE 40 41 samples to meta-analysis (in total, 10,544 OUD cases and 72,163 opioid-exposed controls). A 42 functional coding variant (rs1799971, encoding Asn40Asp) in OPRM1 (mu opioid receptor gene, the main biological target for opioid drugs) reached GWS ( $p=1.51 \times 10^{-8}$ ); then replicated in two 43 44 independent samples (each at p < 0.05). The final meta-analyzed p-value for this variant in all samples was 7.81×10<sup>-10</sup>. SNP-based heritability of OUD was 11.3%. OUD was genetically 45 correlated with 83 traits, including multiple substance use traits, psychiatric illnesses, cognitive 46 47 performance, and others. Mendelian Randomization revealed possible causal effects on OUD risk from tobacco smoking, major depression, neuroticism, and cognitive performance. Despite 48 the inclusion of data from the MVP, discovery of a significant association depended on including 49 50 other purpose-collected samples as well. Recruitment of additional opioid dependent subjects for future studies – especially of non-European ancestry – is a crucial next step. 51

# 52 Introduction

Opioid abuse, addiction, and overdose are at epidemic levels in the United States. Opioids are 53 54 the leading cause of overdose deaths, and their use has increased dramatically in recent 55 decades [1]. A multifaceted approach is needed to address the opioid crisis, including improving 56 our understanding of the biological mechanisms of opioid addiction. Opioids exert their 57 biological effects primarily by binding (mainly in brain and peripheral nervous tissues) to the opioid receptors  $mu(\mu)$ , kappa ( $\kappa$ ), and delta ( $\delta$ ), which are encoded by OPRM1, OPRK1, and 58 OPRD1, respectively [2]. Numerous candidate-gene association studies of these genes 59 (especially OPRM1) and those encoding related proteins have been conducted in the past two 60 61 decades (reviewed in ref [3, 4]), but prior studies have failed consistently to demonstrate 62 association (e.g., studies on OPRM1\*rs1799971 are reviewed in ref [5]). However, a prior genome-wide association study (GWAS) of opioid dosing reported a genome-wide significant 63 64 (GWS) association mapping upstream of the OPRM1 locus [6].

65 Rs1799971 (A118G, encoding Asn40Asp) [5, 7], a functional variant, is one of the most studied candidate variants for substance use traits. While no consistent results were observed. 66 this could reflect limited power and population heterogeneity of previous studies (allele 67 frequency varies greatly in different populations [8, 9]). Several kinds of evidence support 68 69 possible functional effects of this SNP: rs1799971 reportedly alters beta-endorphin binding and 70 activity [7], may be associated with cortisol response to naloxone blockade [10], and may be 71 associated with neurobehavioral functions in a mouse model [11, 12] and human induced 72 pluripotent stem cell lines [13].

Several GWAS of DSM-IV opioid dependence [OD] yielded significant findings [14-16];
one included internal replication [16] but none reported clear external replication, probably due
to the limited sample sizes available (the largest study so far included 2,015 OD cases [16]).
The risk variants identified map to *APBB2*, *PARVA*, *KCNC1*, and *KCNC2* [14] in African-

American (AA) samples, and *CNIH3* [15] and *RGMA* [16] in European ancestry samples. There have also been GWAS of related traits including therapeutic opioid dose (noted above) [6], and opioid overdose (which identified one variant near *MCOLN1* in AAs) [17]. Of these, only the study on opioid dosing included an external validation. No GWAS yet has been sufficiently powered to estimate the SNP-based heritability ( $h^2$ ) of OD.

We conducted GWAS on ICD (International Classification of Diseases)-9/10-diagnosed 82 opioid use disorder (OUD) and opioid-exposed controls) in 79,729 European Americans (EAs) 83 from the Million Veteran Program (MVP). Then we meta-analyzed for OUD combining MVP, 84 Yale-Penn, and the Study of Addiction: Genetics and Environment (SAGE) samples [18]. The 85 latter two samples were included in our previous publication [16], but were reanalyzed here as a 86 87 binary diagnostic trait rather than a criterion count for better congruence with available MVP 88 information. Rs1799971 was the only variant that was GWS (p=1.51×10<sup>-8</sup>) in this meta-analysis. 89 We then replicated the result in two independent samples. We estimated the  $h^2$  and detected 90 genetic correlations between OUD and a variety of psychiatric traits. Causal effects of 91 substance use, psychiatric diseases, and educational attainment on liability to OUD were also detected. 92

93

#### 94 Methods

95 MVP datasets. The MVP is a cross-sectional mega-biobank supported by the U.S. Department 96 of Veterans Affairs (VA). Enrollment in MVP began in 2011 and is ongoing. Phenotypic data 97 were collected using the VA electronic health record (EHR), and blood samples were obtained 98 for genetic studies [19]. Two phases of genotypic data have been released according to their 99 genotyping epochs and were included in this study. MVP phase1 contains 353,948 subjects, of 90 whom 209,020 were defined previously as EAs [20]. MVP phase2 contains 108,416 subjects.

We used the same process as in MVP phase1 for quality control and to define EAs (see
Supplementary Methods) [20]; there were 67,268 EA subjects.

Cases were participants with at least one inpatient or two outpatient ICD-9/10 codes for 103 OUD (Supplementary Table 1) between 2000 and 2018. In MVP phase1, there were 6,367 OUD 104 105 EAs (3.04% prevalence), and 2,162 OUD EAs (3.21% prevalence) in MVP phase2 were 106 included in this study. Stringent criteria were applied to define incident opioid-exposed controls (see details in ref [21]). In short, we started with all MVP participants and excluded subjects with 107 108 exposure to a prescription opioid <7 consecutive days, or with VA follow-up less than 6 months 109 after baseline, or with cancer diagnosed before or after baseline, or with baseline opioid dosage >90 mg morphine equivalent daily dose (MEDD), or with OUD diagnosis or OUD 110 111 treatment at baseline. For the remaining participants, a latent growth mixture model was applied 112 to identify the major classes of opioid dose (measured by MEDD) trajectories that assigned 113 each individual to the trajectory with the highest probability of membership. Four resultant 114 MEDD trajectories were designated as low, moderate, escalating, and rapidly escalating. To 115 minimize the potential rate of false negatives in the control group, subjects assigned to the lowdose trajectory without an incident OUD diagnosis during follow-up were defined as controls, 116 117 yielding 55,429 and 15,771 EA controls in MVP phaes1 and MVP phase2, respectively.

Genotyping in MVP was performed using a customized Affymetrix Biobank Array.
Imputation and quality control metrics for MVP phase1 were as described previously [20].
Similar processes were used for MVP phase2 (see Supplementary Methods). GWAS was then
performed on the MVP datasets. We used logistic regression implemented in PLINK v1.90b4.4
[22] for the OUD GWAS correcting for age, sex, and the first 10 principal components (PCs).

123

124

Ethics statement: The Central VA Institutional Review Board (IRB) and site-specific IRBs

approved the MVP study. All relevant ethical regulations for work with human subjects were

followed in the conduct of the study, and written informed consent was obtained from all

127 participants.

128

129 Yale-Penn and SAGE datasets. GWAS for DSM-IV OD criterion counts were performed

previously, including three phases of Yale-Penn data, and the SAGE cohort (dbGaP study id

phs000092.v1.p1) [16]. We re-analyzed these data using OUD diagnosis. See Supplementary

132 Methods.

133

Meta-analyses. Sample-size-weighted meta-analyses were performed using METAL [23].
Given the unbalanced ratios of cases to controls in MVP samples, effective sample sizes were
calculated as follow:

137 
$$n_{effective} = \frac{4}{\frac{1}{n_{case}} + \frac{1}{n_{control}}}$$

The calculated effective sample sizes in MVP were used in meta-analyses and all downstream analyses. Only variants present at least in MVP phase1, which is the largest sample (~75% of the total), and with heterogeneity test p-value >5×10<sup>-8</sup> were retained, leaving 5.7 M variants.

141

Replication in independent samples. In Yale-Penn, 4,817 subjects were recently added and
not included in any prior analysis. We genotyped them using the Illumina Multi-Ethnic
Genotyping Array (San Diego, CA) which includes ~1.7 M SNPs. Subjects with mismatched
genotypic and phenotypic sex were removed, as were subjects with excessive heterozygosity.
Duplicate subjects with respect to the Yale-Penn discovery samples were removed. The

147	remaining subjects were classified into population groups as for MVP. Among the 2,041
148	genetically classified EAs, 508 were diagnosed as DSM-IV OD cases, and 206 were opioid
149	exposed controls. GEMMA was used for an association test only for rs1799971 (i.e., no other
150	markers were evaluated) and corrected for age, sex, and the first 10 PCs.
151	In the UK Biobank (UKB), we looked up the association between rs1799971 (only this
152	marker, as for the other replication sample) and buprenorphine treatment (mostly used to treat
153	OUD; treatment/medication code: 20003_1140871732) in the UKB. We examined GWAS
154	summary data released by the Neale lab (information available at http://www.nealelab.is/uk-
155	biobank) for 240 cases and 360,901 controls differentiated based on buprenorphine treatment.
156	
157	<b>SNP-based</b> $h^2$ . LD Score Regression (LDSC) [24] was used to estimate the SNP-based $h^2$
158	using 1000 Genomes Project Europeans [8] as the LD reference panel. The major
159	histocompatibility complex (MHC) region (chr6: 26–34Mb) was excluded. Effective sample size
160	was used in LDSC.
161	
162	<b>Genetic correlation.</b> We estimated the genetic correlation ( $r_g$ ) between OUD and 715 publicly
163	available traits from LD Hub [25] or other resources using LDSC (Supplementary Table 2) [26].
164	Among the tested traits, 232 were published previously, and 483 from the UKB were
165	unpublished, but integrated in LD Hub. Bonferroni correction was applied and correlation was
166	considered significant at a p-value threshold of 6.99×10 <sup>-5</sup> .
167	
168	Mendelian Randomization. We used Mendelian randomization (MR) to investigate whether

169 exposures (based on 18 published traits that were significantly correlated with OUD  $[r_g]$ 

170 p<6.99×10<sup>-5</sup>) have causal effects on the liability to OUD. For instrumental variants missing in 171 the OUD summary data, we used the results of the best proxy variant in highest LD ( $r^2$ >0.8) with the missing variant. If the MAF of the missing variant was <0.01, or none of the variants within 172 200 kb had LD  $r^2$ >0.8, we removed the instrumental variant from the analysis. Palindromic 173 174 SNPs (A/T or G/C alleles) with MAF [0.4, 0.5] in the OUD summary data were also removed or 175 replaced with the best proxy variant. For robust causal effect inference, we limited the traits studied to those with >30 available instruments. Accordingly, 12 exposures were analyzed. We 176 177 used weighted median [27], inverse-variance weighted (IVW, random-effects model) [28], and 178 MR-Egger [29], implemented in the R package "MendelianRandomization v0.3.0" [30] for MR inference. Evidence of pleiotropic effects was examined by the MR-Egger intercept test, where 179 a non-zero intercept (p<0.05) indicates directional pleiotropy [29]. Whereas MR analyses 180 require the beta (effect size) and standard error, we calculated these using Z-scores (z), allele 181 182 frequency (p) and sample size (n) from the OUD meta-analyses [31]:

$$beta = \frac{z}{\sqrt{2p(1-p)(n+z^2)}}.$$
  

$$SE = \frac{1}{\sqrt{2p(1-p)(n+z^2)}}.$$

184

#### 185 Results

# 186 Association results for opioid use disorder (OUD)

In MVP phase1, 6,367 subjects were diagnosed as OUD cases, and 55,429 subjects were defined as controls. 2,162 cases and 15,771 controls were included from MVP phase2 (Table 1). We meta-analyzed the 8,529 OUD cases and 71,200 controls within MVP (totaling 79,729 individuals, Table 1), and no variant reached GWS ( $p<5\times10^{-8}$ , Supplementary Figure 1). The variant with the smallest p-value was rs1799971 in the *OPRM1* gene ( $p=5.90\times10^{-8}$ ,

 $n_{\text{effective}}$ =30,443; the minor G allele is protective with beta=-0.142 and se=0.026).

193

Samples	# Cases	# Controls	Age (mean+SD)	%female
MVP phase1	6,367	55,429	61.2 (13.0)	9.3
MVP phase2	2,162	15,771	61.2 (13.7)	9.7
Sub-total	8,529	71,200	61.2 (13.2)	9.4
Yale-Penn 1	1,043	294	36.9 (10.3)	40.5
Yale-Penn 2	724	243	36.4 (11.4)	33.0
Yale-Penn 3	54	44	33.6 (11.6)	41.8
SAGE	194	382	35.8 (9.1)	33.9
Sub-total	2,015	963	36.4 (10.5)	36.8
Total	10,544	72,163		

#### 194 **Table 1. Demographics – discovery sample.**

195

196

197 We then meta-analyzed the MVP samples with Yale-Penn (three tranches) and SAGE 198 samples, bringing the total sample size to 82,707 (10,544 cases and 72,163 opioid-exposed controls, Table 1). This represents a 24% increase in the number of cases. The OD cases in 199 Yale-Penn and SAGE were diagnosed using DSM-IV, and the controls were opioid exposed 200 (this differs from our previously published GWAS [16], which defined phenotype based on DSM-201 202 IV OD criterion count). From the meta-analysis, SNP-based heritability ( $h^2$ ) was 0.113 203 (se=0.018) estimated by LD Score Regression (LDSC). The association of rs1799971 with OUD was GWS (beta=-0.066, se=0.012, p=1.51×10<sup>-8</sup>, n<sub>effective</sub>=33,421, Figure 1, Supplementary 204 Figure 2). The effects were all in the same direction except for SAGE, which might be due to 205

206 limited sample size. There were no significant results from gene-based association and gene-

# set analyses.

Samples	N (#case)	р	
MVP phase1 <sup>a</sup>	61,796 (6,367)	1.14 × 10 <sup>-4</sup>	
MVP phase2 <sup>a</sup>	17,933 (2,162)	2.49 × 10 <sup>-5</sup>	
Yale-Penn 1⁵	1,337 (1,043)	0.558	
Yale-Penn 2⁵	967 (724)	0.039	-8-
Yale-Penn 3⁵	98 (54)	0.440	
SAGE⁵	576 (192)	0.698	
meta−analysisº	82,707 (10,544)	1.51 × 10 <sup>-8</sup>	•
			-0.3 -0.2 -0.1 0 0.1
			Beta or log(OR) (95% CI)

208

Figure 1. Associations between rs1799971\*G and OUD. <sup>a</sup>Logistic regression was applied on unrelated case/control samples in MVP, log(OR) is presented; <sup>b</sup>a linear mixed model was applied on complex family-based samples, beta is presented; <sup>c</sup>effective sample size weighted meta-analysis was applied, and beta is presented.

213

# 214 Replication in independent samples

- In total, 714 EAs (508 OD cases and 206 opioid-exposed controls) were analyzed in the new
- 216 Yale-Penn samples, and rs1799971\*G was associated with reduced OD risk (i.e., in the same
- direction as the discovery meta-analysis) (beta=-0.074, se=-0.038, p=0.049). In the UKB,
- rs1799971\*G was negatively associated with buprenorphine treatment status (240 cases and
- 360,901 controls, beta=-1.90×10<sup>-4</sup>, se=9.13×10<sup>-5</sup>, p=0.038), also consistent with the direction of
- 220 effect in the discovery sample. Meta-analysis of discovery and replication cohorts for this variant
- yielded a p-value of  $7.81 \times 10^{-10}$ .

222

# 223 Genetic correlations with other traits

We estimated the genetic correlations ( $r_g$ ) between OUD and 715 traits with publicly available

summary statistics using LDSC. Among those traits, 232 were published, and 483 were

226 unpublished and derived from UKB data. OUD was significantly correlated with 83 of these traits 227 (Supplementary Table 2). Figure 1 depicts 18 correlated traits from published literature (Supplementary Methods). Among the correlated substance use-related traits, "ever smoked 228 229 regularly" showed the highest correlation with OUD ( $r_{a}$ =0.51, se=0.06, p=3.37×10<sup>-19</sup>), followed 230 by "opioid medication use" in UKB ( $r_a$ =0.48, se=0.07, p=1.61×10<sup>-11</sup>). Both "problematic alcohol 231 use" (measured by alcohol dependence and AUDIT-P [Alcohol Use Disorders Identification Test-Problems] score) and "alcohol use quantity" (measured by drinks per week) showed high 232 genetic correlations with OUD. "Unable to stop smoking" (current vs. former smoker), and 233 234 "earlier age of smoking initiation" were also correlated with OUD. However, correlations with AUDIT-C (Alcohol Use Disorders Identification Test-Consumption), total AUDIT, cigarettes per 235 day, and lifetime cannabis use were not significant after Bonferroni correction. Several 236 237 psychiatric traits were correlated with OUD, including attention deficit hyperactivity disorder 238 (ADHD,  $r_{q}$ =0.36, se=0.07, p=6.78×10<sup>-7</sup>), major depressive disorder (MDD,  $r_{q}$ =0.35, se=0.06,  $p=1.62 \times 10^{-10}$ ), schizophrenia ( $r_{a}=0.29$ , se=0.05, p=1.93 × 10^{-8}), neuroticism ( $r_{a}=0.27$ , se=0.05, 239 240 p=8.65×10<sup>-8</sup>), and neuroticism subclusters. OUD was positively correlated with risk-taking behavior and insomnia, and negatively correlated with cognitive traits and age of first birth. 241 242 These finding are consistent with the known adverse medical, psychiatric, and social 243 consequences of OUD.



### 244

Figure 2. Genetic correlations between OUD and published traits. Listed are the 18
published traits significantly correlated with OUD. *N02A: Opioid*: self-reported medication-use of
opioid drugs (Anatomical Therapeutic Chemical [ATC] Classification code: N02A) in UK
Biobank; *PGC*: Psychiatric Genomics Consortium; *AUDIT-P*: the Alcohol Use Disorders
Identification Test–Problems; *ADHD*: attention deficit hyperactivity disorder, *MDD*: major
depressive disorder; *Depressed affect subcluster*: depressed affect neuroticism subcluster; *Worry subcluster*: worry neuroticism subcluster.

252

# 253 Mendelian Randomization

Using MR, we explored possible causal effects of exposures on OUD (Table 2). Among the 12

tested exposures, five supported a possible causal effect on liability to OUD by at least one

256 method and without evidence of horizontal pleiotropy (MR-Egger intercept p>0.05): positively

with ever smoked regularly, MDD, neuroticism and worry neuroticism subcluster, and negatively

with educational attainment. There was weak evidence of a causal effect of drinks per week on

OUD risk by the IVW method, but the estimate could be biased due to horizontal pleiotropy.

# Table 2. Causal effects on OUD by MR.

Exposure (#instruments)	IVW		Weighted median		MR-Egger		MR-Egger
	β (se)	р	β (se)	р	β (se)	р	intercept p
Ever smoked regularly (197)	0.33 (0.04)	1.88×10 <sup>-19</sup>	0.28 (0.05)	4.79×10 <sup>-8</sup>	0.18 (0.14)	0.206	0.264
Drinks per week (63)	0.31 (0.10)	1.31×10 <sup>-3</sup>	0.23 (0.13)	0.078	-0.04 (0.16)	0.820	8.77×10 <sup>-3</sup>
MDD (78)	0.18 (0.05)	6.21×10 <sup>-4</sup>	0.17 (0.06)	4.28×10 <sup>-3</sup>	-0.25 (0.34)	0.468	0.202
Schizophrenia (108)	0.03 (0.01)	0.020	0.03 (0.02)	0.097	-0.01 (0.07)	0.825	0.439
Neuroticism (131)	0.22 (0.06)	4.07×10 <sup>-4</sup>	0.16 (0.08)	0.050	0.19 (0.27)	0.468	0.934
Depressed affect subcluster (55)	0.32 (0.10)	2.12×10 <sup>-3</sup>	0.34 (0.12)	4.01×10 <sup>-3</sup>	-0.35 (0.50)	0.482	0.173
Worry subcluster (61)	0.28 (0.09)	1.32×10 <sup>-3</sup>	0.15 (0.11)	0.157	0.24 (0.40)	0.545	0.919
Number of sexual partners (64)	0.27 (0.09)	1.77×10 <sup>-3</sup>	0.18 (0.10)	0.083	0.43 (0.40)	0.283	0.689
General risk tolerance (64)	0.16 (0.13)	0.212	0.18 (0.16)	0.257	0.45 (0.58)	0.438	0.608
Insomnia (158)	0.06 (0.02)	3.45×10 <sup>-3</sup>	0.03 (0.03)	0.226	-0.03 (0.09)	0.731	0.275
Educational attainment (564)	-0.32 (0.04)	2.34×10 <sup>-16</sup>	-0.33 (0.05)	4.09×10 <sup>-10</sup>	-0.18 (0.15)	0.222	0.311
Cognitive performance (133)	-0.12 (0.05)	9.72×10 <sup>-3</sup>	-0.11 (0.06)	0.061	0.03 (0.22)	0.894	0.477

P-values in bold are significant after multiple testing correction (significant threshold, 0.05/36=1.39×10<sup>-3</sup>). Traits labeled in bold are

those having a causal effect on OUD by at least one method without evidencing horizontal pleiotropy (MR-Egger intercept p>0.05).
 IVW: inverse-variance weighted (IVW) linear regression. MDD: major depressive disorder. Depressed affect subcluster: depressed

265 affect subcluster of neuroticism. Worry subcluster: worry subcluster of neuroticism.

#### 266 Discussion

Opioid use is at epidemic levels in the United States and is a major cause of death and disability 267 worldwide. Understanding the genetic architecture of OUD might provide clinically useful clues 268 269 about its biology. However, only a few risk variants have been identified by GWAS so far, and 270 none has had clear external replication. Several factors contribute to this situation: 1). OUD is a 271 complex psychiatric disease with relatively low heritability, and there is no single variant with large effect size that can be detected in small cohorts (contrary to, for example, alcohol 272 273 dependence [32] with ADH1B, and nicotine dependence with the chromosome 15 nicotine 274 receptor cluster [33]); 2). Previous OUD GWAS were relatively small compared to those for 275 legal substance use disorders (e.g., the number of alcohol use disorder cases reached 57,564 276 in a large meta-analysis [34]); 3). In published work relevant to opioid use, there was 277 considerable phenotypic heterogeneity across samples. The ascertainment of OUD cases (e.g., ICD-diagnosed OUD in the EHR, DSM-IV-assessed OD, patients receiving opioid substitution 278 279 therapy, and daily injectors of illicit opioids) and controls (e.g., opioid exposed, or random 280 population with unknown opioid exposure status) differ by study. One way to reach a better understanding of OUD genetics is increasing the sample size in a homogeneous cohort. 281

282 We conducted GWAS of OUD in a large cohort, the MVP, comprising 8,529 cases and 283 71.200 opioid-exposed controls of European ancestry. Most previously reported variants 284 associated with a wide range of opioid-related traits were not significant in MVP (cf. summary 285 statistics). For some, this reflects lack of marker information or LD proxies in the MVP, or the lack of non-European populations in this analysis; some associations were previously reported 286 287 in African-ancestry populations only [14]; others were reported in EAs, but relevant variants are missing in the MVP data (e.g., rs12442183 near RGMA reported by Cheng et al. [16] was 288 289 filtered by low genotype call rate in imputation). No variant reached GWS in this largest-ever cohort individually; OPRM1\*rs1799971 was nominally significantly associated with OUD 290

(p=5.90×10<sup>-8</sup>). We meta-analyzed MVP samples with Yale-Penn and SAGE (re-analyzed here
as case/control rather than the quantitative criterion count traits reported originally, to match the
available phenotype from the MVP more closely), increasing total sample size to 82,707 (10,544
cases and 72,163 opioid-exposed controls). By adding four samples from Yale-Penn and
SAGE, rs1799971 reached GWS. The final meta-analyzed p-value for this marker is 1.51×10<sup>-8</sup>
(excluding independent replications).

Rs1799971 (A118G) maps to exon 1 of the mu opioid receptor (OPRM1) gene, causing 297 298 an amino acid change from asparagine to aspartic acid. Extensive candidate studies of this 299 variant with a wide range of addictive and other behavioral traits have been conducted over two decades. Associations between rs1799971 and opioid-related traits have not been consistent 300 301 [5]. We conducted hypothesis-free, genome-wide analyses for OUD and detected association at 302 rs1799971 by almost guintupling the number of cases compared to any previous studies [5, 16]. 303 Our increment in exposed controls, which have often been even more limiting than affected 304 OUD subjects in previous studies, is even greater. Since many individuals exposed to opioids become dependent, an unassessed control group is not an ideal alternative to an opioid-305 exposed control group even if greater numbers of subjects can be achieved - because the 306 307 former group is more correctly "diagnosis unknown" and inevitably contains many subjects genetically predisposed to OUD who would express that phenotype had they been exposed. We 308 sought replication in two independent samples. One included newly genotyped Yale-Penn 309 310 subjects, and the other, a proxy-phenotype buprenorphine treatment sample from the UKB. The 311 association was replicated in each of these samples.

Although we still encounter a relative lack of power overall as indicated by no additional variant detected beyond rs1799971, a lack of any significant gene associated in gene-based analysis, and no gene-set enrichment, there is reasonable power for genetic correlation. Multiple substance use-related traits including smoking, alcohol, and opioid use and psychiatric

316 traits were among the top correlates. Several smoking traits were positively correlated with 317 OUD, consistent with the strong correlation between nicotine use and opioid use disorder [35, 36]. MR analysis provided evidence (considered weak, as it is not supported by all the three 318 319 tested methods) that the genetic liability to substance use related traits has causal effects on 320 susceptibility to OUD. Medical opioid use is correlated with OUD, as expected. And problematic 321 alcohol use (measured by AD and AUDIT-P score) and drinking quantity are also genetically 322 correlated with OUD. Thus, it may be feasible for prevention or treatment efforts directed at 323 legal substance use to reduce the burden of consequent opioid dependence. Psychiatric traits 324 including ADHD, MDD, schizophrenia, and neuroticism are genetically correlated with OUD, 325 consistent with phenotypic evidence [37, 38]. Weak evidence from MR analyses also indicated possible causal effects on OUD risk of MDD and neuroticism. 326

327 We note limitations of this study. First, the sample size, though a major improvement, is 328 still not as large as what can be obtained for legal substance use-related traits, and this limited 329 power to detect more GWS signals and to obtain insight into OUD biological mechanisms. Legal 330 substance use traits are more common, and data pertinent to these traits is collected more commonly than for illegal traits in biobanks and EHRs. Second, the phenotypes in the samples 331 332 we studied were not identical. The MVP used ICD 9/10-diagnosed OUD. We expect false negatives in a sample like the MVP, owing to stigma and insufficient vigilance on the part of 333 treatment teams concentrating mostly on medical illness, but few false positives. Overall, we 334 believe these diagnoses to be guite useful, as false positives would be more of a problem than 335 336 false negatives. Third, the only GWS variant, rs1799971, has a very small effect size (beta=-337 0.066). The association was close to GWS in MVP alone, and improved by meta-analysis. High quality genotype data and replication in an independent sample were required. Rs1799971 was 338 339 genotyped directly (was not imputed) in all samples, discovery and replication. Fourth, the 340 replication samples are small (508 OD cases in the new Yale-Penn sample and 240

341 buprenorphine treatment cases in UKB), and the associations only nominally significant 342  $(p\sim0.05)$ . We examined only this one marker in the replication samples, so nominal significance should be a sufficient test of replication (and arguably a 1-tailed test could have been applied 343 344 rather than the more stringent 2-tailed test applied here). The phenotype in UKB is a proxy 345 phenotype-buprenorphine treatment. Although buprenorphine is a first-line drug for OUD 346 treatment, it could have been used for other purposes in the UKB population, including pain 347 management; but if this is true to any considerable extent, it should reduce our power to detect 348 an association due to added noise, rather than lead to a false positive finding. Fifth, we only 349 studied samples with European ancestry. There has been a lack of recruitment for non-European populations globally, e.g., only a few GWASs have been conducted in AAs [6, 14] in 350 smaller cohorts. 351

352 In summary, we report here the largest GWAS and the largest meta-analysis for OUD so 353 far. This finding may not have direct implications for personalized medicine – because the 354 relevant gene is already the main physiological target of all opioids, illegal and therapeutic; providing, at least, a "proof of principle" of relevance of the finding, OUD is genetically correlated 355 with substance use traits, other psychiatric traits, insomnia, and cognitive performance. Among 356 357 these, ever smoked regularly, MDD, neuroticism, and cognitive performance have potential causal or protective effects on the liability of OUD, which provides clues for future prevention 358 359 efforts. Recruitment of additional OUD subjects - especially of non-European ancestry - is a 360 crucial next step. Considering the general lack of private foundation funding for study of 361 substance use disorders, it is likely that government-supported funding agencies will be required to accomplish this goal. 362

363

#### 364 Acknowledgements

365 This research used data from the Million Veteran Program. Office of Research and 366 Development, Veterans Health Administration, and was supported by award #1101BX003341. This publication does not represent the views of the Department of Veterans Affairs or the 367 368 United States Government. Supported also by a NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation (HZ). Dr. Gelernter was supported by National Institutes 369 of Health grants RC2 DA028909, R01 DA12690, R01 DA12849, R01 DA18432, R01 AA11330, 370 and R01 AA017535, the New England MIRECC, and by the Department of Veterans Affairs 371 Medical Research Program. Dr. Kranzler was supported by National Institutes of Health grants 372 373 R21 DA10242 and R01 DA18432 and both he and Dr. Kember were supported by the VISN 4 MIRECC. Genotyping services for a part of the Yale-Penn GWAS study were provided by the 374 375 Center for Inherited Disease Research (CIDR) and Yale University (Center for Genome Analysis). CIDR is fully funded through a federal contract from the National Institutes of Health 376 377 to The Johns Hopkins University (contract number N01-HG-65403).

378

The publicly available dataset of Study of Addiction: Genetics and Environment (SAGE) used for 379 the analysis was obtained from dbGaP at https://www.ncbi.nlm.nih.gov/projects/gap/cgi-380

bin/study.cgi?study\_id=phs000092.v1.p1. Funding support for SAGE was provided through the 381

382 NIH (U01 HG004422). SAGE is one of the genome-wide association studies funded as part of

the Gene Environment Association Studies (GENEVA) under Genes, Environment and Health 383

Initiative (GEI). Assistance with phenotype harmonization and genotype cleaning, as well as 384

385 with general study coordination, was provided by the GENEVA Coordinating Center (U01 HG004446). 386

387

388 We also thank Ann Marie Lacobelle, and Christa Robinson who provided technical assistance 389 for the genotyping.

390

Disclosures: Dr. Kranzler is a member of the American Society of Clinical 391

392 Psychopharmacology's Alcohol Clinical Trials Initiative, which in the past three years was

supported by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor, and 393

Amygdala Neurosciences. Drs. Kranzler and Gelernter are named as inventors on PCT patent 394

395 application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists," filed January 24, 2018.

396

#### 398 References

399 1. Jalal, H., et al., Changing dynamics of the drug overdose epidemic in the United States from 1979 400 through 2016. Science, 2018. 361(6408). 401 2. Darcq, E. and B.L. Kieffer, Opioid receptors: drivers to addiction? Nat Rev Neurosci, 2018. 19(8): 402 p. 499-514. 403 Reed, B., et al., Genetics of opiate addiction. Curr Psychiatry Rep, 2014. 16(11): p. 504. 3. 404 4. Mistry, C.J., et al., Genetics of Opioid Dependence: A Review of the Genetic Contribution to 405 Opioid Dependence. Curr Psychiatry Rev, 2014. 10(2): p. 156-167. 406 5. Schwantes-An, T.H., et al., Association of the OPRM1 Variant rs1799971 (A118G) with Non-407 Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of 408 European-Ancestry Cohorts. Behav Genet, 2016. 46(2): p. 151-69. 409 6. Smith, A.H., et al., Genome-wide association study of therapeutic opioid dosing identifies a novel 410 locus upstream of OPRM1. Mol Psychiatry, 2017. 22(3): p. 346-352. 411 7. Bond, C., et al., Single-nucleotide polymorphism in the human mu opioid receptor gene alters 412 beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad 413 Sci U S A, 1998. 95(16): p. 9608-13. 414 8. 1000 Genomes Project Consortium, et al., A global reference for human genetic variation. 415 Nature, 2015. 526(7571): p. 68-74. 416 9. Gelernter, J., H. Kranzler, and J. Cubells, Genetics of two mu opioid receptor gene (OPRM1) exon 417 I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent 418 subjects. Mol Psychiatry, 1999. 4(5): p. 476-83. 10. 419 Chong, R.Y., et al., The mu-opioid receptor polymorphism A118G predicts cortisol responses to 420 naloxone and stress. Neuropsychopharmacology, 2006. **31**(1): p. 204-11. 421 11. Zhang, Y., et al., Mouse model of the OPRM1 (A118G) polymorphism: differential heroin self-422 administration behavior compared with wild-type mice. Neuropsychopharmacology, 2015. 40(5): 423 p. 1091-100. 424 12. Robinson, J.E., et al., Receptor Reserve Moderates Mesolimbic Responses to Opioids in a 425 Humanized Mouse Model of the OPRM1 A118G Polymorphism. Neuropsychopharmacology, 426 2015. 40(11): p. 2614-22. 427 13. Halikere, A., et al., Addiction associated N40D mu-opioid receptor variant modulates synaptic 428 function in human neurons. BioRxiv, 2018. http://dx.doi.org/10.1101/328898. 429 14. Gelernter, J., et al., Genome-wide association study of opioid dependence: multiple associations 430 mapped to calcium and potassium pathways. Biol Psychiatry, 2014. **76**(1): p. 66-74. 431 15. Nelson, E.C., et al., Evidence of CNIH3 involvement in opioid dependence. Mol Psychiatry, 2016. 432 21(5): p. 608-14. 433 16. Cheng, Z., et al., Genome-wide Association Study Identifies a Regulatory Variant of RGMA 434 Associated With Opioid Dependence in European Americans. Biol Psychiatry, 2018. 84(10): p. 435 762-770. 436 17. Cheng, Z., et al., Genome-wide scan identifies opioid overdose risk locus close to MCOLN1. Addict 437 Biol, 2019: p. e12811. 438 18. Edenberg, H.J., The collaborative study on the genetics of alcoholism: an update. Alcohol Res 439 Health, 2002. 26(3): p. 214-8. 440 19. Gaziano, J.M., et al., Million Veteran Program: A mega-biobank to study genetic influences on 441 health and disease. J Clin Epidemiol, 2016. 70: p. 214-23. 442 20. Kranzler, H.R., et al., Genome-wide association study of alcohol consumption and use disorder in 443 274,424 individuals from multiple populations. Nat Commun, 2019. 10(1): p. 1499.

444	21.	Rentsch, C.T., et al., Patterns and Correlates of Prescription Opioid Receipt Among US Veterans:
445		A National, 18-Year Observational Cohort Study. AIDS Behav, 2019.
446	22.	Chang, C.C., et al., Second-generation PLINK: rising to the challenge of larger and richer datasets.
447		Gigascience, 2015. <b>4</b> : p. 7.
448	23.	Willer, C.J., Y. Li, and G.R. Abecasis, METAL: fast and efficient meta-analysis of genomewide
449		association scans. Bioinformatics, 2010. 26(17): p. 2190-1.
450	24.	Bulik-Sullivan, B.K., et al., LD Score regression distinguishes confounding from polygenicity in
451		genome-wide association studies. Nat Genet, 2015. 47(3): p. 291-5.
452	25.	Zheng, J., et al., LD Hub: a centralized database and web interface to perform LD score regression
453		that maximizes the potential of summary level GWAS data for SNP heritability and genetic
454		correlation analysis. Bioinformatics, 2017. 33(2): p. 272-279.
455	26.	Bulik-Sullivan, B., et al., An atlas of genetic correlations across human diseases and traits. Nat
456		Genet, 2015. <b>47</b> (11): p. 1236-41.
457	27.	Bowden, J., et al., Consistent Estimation in Mendelian Randomization with Some Invalid
458		Instruments Using a Weighted Median Estimator. Genet Epidemiol, 2016. 40(4): p. 304-14.
459	28.	Bowden, J., et al., A framework for the investigation of pleiotropy in two-sample summary data
460		Mendelian randomization. Stat Med, 2017. <b>36</b> (11): p. 1783-1802.
461	29.	Bowden, J., G. Davey Smith, and S. Burgess, Mendelian randomization with invalid instruments:
462		effect estimation and bias detection through Egger regression. Int J Epidemiol, 2015. 44(2): p.
463		512-25.
464	30.	Yavorska, O.O. and S. Burgess, MendelianRandomization: an R package for performing
465		Mendelian randomization analyses using summarized data. Int J Epidemiol, 2017. <b>46</b> (6): p. 1734-
466		1739.
467	31.	Zhu, Z., et al., Integration of summary data from GWAS and eQTL studies predicts complex trait
468		gene targets. Nat Genet, 2016. <b>48</b> (5): p. 481-7.
469	32.	Gelernter, J., et al., Genome-wide association study of alcohol dependence:significant findings in
470		African- and European-Americans including novel risk loci. Mol Psychiatry, 2014, <b>19</b> (1): p. 41-9.
471	33.	Tobacco Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated
472		with smoking behavior. Nat Genet. 2010. <b>42</b> (5): p. 441-7.
473	34.	Zhou, H., et al., Meta-analysis of problematic alcohol use in 435.563 individuals identifies 29 risk
474		variants and vields biological insights, pervasive pleiotropy and evidence of causality, bioRxiv,
475		2019.
476	35.	Clemmey, P., et al., Smoking habits and attitudes in a methodone maintenance treatment
477		population. Drug Alcohol Depend. 1997. <b>44</b> (2-3): p. 123-32.
478	36.	Richter, K.P., et al., Tobacco use and quit attempts among methodone maintenance clients. Am L
479		Public Health, 2001, <b>91</b> (2): p. 296-9.
480	37.	Sullivan, M.D., et al., Association between mental health disorders, problem drug use, and
481		regular prescription opioid use. Arch Intern Med. 2006. <b>166</b> (19): n. 2087-93
482	38	Seal, K.H., et al., Association of mental health disorders with prescription onioids and high-risk
483	00.	onioid use in US veterans of Iraa and Afahanistan IAMA 2012 <b>307</b> (9): n 940-7
.00		